Lakeshore Biopharma (LSB) Institutional Ownership $2.24 -0.16 (-6.46%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$2.22 -0.03 (-1.34%) As of 02/21/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Lakeshore Biopharma (NASDAQ:LSB)CurrentInstitutional OwnershipPercentage52.64%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$16.94MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$3.11M Get LSB Insider Trade Alerts Want to know when executives and insiders are buying or selling Lakeshore Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LSB Institutional Buying and Selling by Quarter Lakeshore Biopharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025 Orbimed Advisors LLC140,428$486K0.0%N/A1.508% 2/14/2025 Hhlr Advisors LTD.75,179$259K0.0%-90.0%0.808% 2/13/2025 Barclays PLC24,757$86K0.0%-90.0%0.266% 11/19/2024 Barclays PLC247,575$169K0.0%N/A2.660% 11/15/2024 Barclays PLC247,575$169K0.0%N/A2.660% 11/14/2024 Hhlr Advisors LTD.751,790$513K0.0%N/A8.075% 11/13/2024 FMR LLC1,165,071$803K0.0%N/A12.514% (Data available from 1/1/2016 forward) LSB Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LSB shares? During the previous two years, the following institutional investors and hedge funds held shares of Lakeshore Biopharma shares: FMR LLC ($803K), Orbimed Advisors LLC ($486K), and Hhlr Advisors LTD. ($259K), Barclays PLC ($86K).Learn more on LSB's institutional investors. What percentage of Lakeshore Biopharma stock is owned by institutional investors? 52.64% of Lakeshore Biopharma stock is owned by institutional investors. Learn more on LSB's institutional investor holdings. Which institutional investors have been buying Lakeshore Biopharma stock? The following institutional investors have purchased Lakeshore Biopharma stock in the last 24 months: FMR LLC ($1.17M), Hhlr Advisors LTD. ($751.79K), Barclays PLC ($495.15K), and Orbimed Advisors LLC ($140.43K). How much institutional buying is happening at Lakeshore Biopharma? Institutional investors have bought a total of 2,552,439 shares in the last 24 months. This purchase volume represents approximately $16.94M in transactions. Which Lakeshore Biopharma major shareholders have been selling company stock? The following institutional investors have sold Lakeshore Biopharma stock in the last 24 months: Hhlr Advisors LTD. ($676.61K), and Barclays PLC ($222.82K). How much institutional selling is happening at Lakeshore Biopharma? Institutional investors have sold a total of 899,429 shares in the last 24 months. This volume of shares sold represents approximately $3.11M in transactions. Related Companies Galectin Therapeutics Institutional Ownership Inozyme Pharma Institutional Ownership Acumen Pharmaceuticals Institutional Ownership Entera Bio Institutional Ownership X4 Pharmaceuticals Institutional Ownership Cellectis Institutional Ownership Scilex Institutional Ownership Protara Therapeutics Institutional Ownership IGM Biosciences Institutional Ownership Aligos Therapeutics Institutional Ownership This page (NASDAQ:LSB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakeshore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakeshore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
